AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 3550340 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 143
Study 30932012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 30932012 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet (1500 kcal/day)
Number of subjects: 15
Study 30932012 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and Hypocaloric diet
Number of subjects: 15
Study 28791820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of botulinum toxin type A (group II)
Number of subjects: 10
Study 28791820 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint therapy (group I)
Number of subjects: 10
Study 25504483 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group (5 training sessions using a prosthesis simulator)
Number of subjects: 48
Study 25504483 — intervention group
Group type: COMPARATOR
Intervention: Control group (only performed the tests)
Number of subjects: 48
Study 23913656 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 45 days
Number of subjects: 33
Study 23913656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 21143421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil (20 mg)
Number of subjects: 49
Study 21143421 — intervention group
Group type: EXPERIMENTAL
Intervention: Vardenafil (20 mg)
Number of subjects: 49
Study 19298296 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.8 mm diameter abutment (test group)
Number of subjects: 22
Study 19298296 — intervention group
Group type: COMPARATOR
Intervention: 5.5 mm diameter abutment (control group)
Number of subjects: 22
Study 19298296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone filling in test group
Number of subjects: 22
Study 19298296 — intervention group
Group type: COMPARATOR
Intervention: Bone filling in control group
Number of subjects: 22
Study 17084785 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 280
Study 17084785 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with fluoxetine
Number of subjects: 280
Study 17084785 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo
Number of subjects: 280
Study 17084785 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 280
Study 15525560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine with high fat meal
Number of subjects: 0
Study 15525560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine with orange juice
Number of subjects: 0
Study 15525560 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine with antacid
Number of subjects: 0
Study 15525560 — intervention group
Group type: COMPARATOR
Intervention: Clofazimine with water (control)
Number of subjects: 0
Study 11765155 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy
Number of subjects: 109
Study 11765155 — intervention group
Group type: COMPARATOR
Intervention: Conventional daylight phototherapy
Number of subjects: 109
Study 9297047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracervical dinoprostone
Number of subjects: 389
Study 9297047 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin infusion
Number of subjects: 389
Study 8277478 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 77
Study 8277478 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and gentamicin
Number of subjects: 77
Study 8277478 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 77
Study 8277478 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failures
Number of subjects: 77
Study 3688387 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine and methohexitone
Number of subjects: 55
Study 3688387 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl and diazepam
Number of subjects: 55
Study 29969431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor
Number of subjects: 304
Study 27752709 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional regulator type II
Number of subjects: 23
Study 27752709 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study 24261460 — intervention group
Group type: EXPERIMENTAL
Intervention: Modifiable extrinsic risk factors
Number of subjects: 132
Study 24261460 — intervention group
Group type: COMPARATOR
Intervention: Female sex
Number of subjects: 132
Study 21806682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-linked collagen membrane (VN)
Number of subjects: 36
Study 21806682 — intervention group
Group type: EXPERIMENTAL
Intervention: Native collagen membrane (BG)
Number of subjects: 36
Study 21806682 — intervention group
Group type: COMPARATOR
Intervention: Control group (absent RDH, 0 mm)
Number of subjects: 36
Study 20723779 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver (CRP)
Number of subjects: 118
Study 20723779 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP plus home exercise
Number of subjects: 118
Study 20723779 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified CRP
Number of subjects: 118
Study 20723779 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP for patients with involvement of two semicircular canals
Number of subjects: 118
Study 20723779 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-CRP home exercise
Number of subjects: 118
Study 20723779 — intervention group
Group type: COMPARATOR
Intervention: Self-CRP
Number of subjects: 118
Study 18854540 — intervention group
Group type: EXPERIMENTAL
Intervention: Episodic amiodarone treatment
Number of subjects: 209
Study 18854540 — intervention group
Group type: COMPARATOR
Intervention: Continuous amiodarone treatment
Number of subjects: 209
Study 16227760 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 150/12.5 mg for 8 weeks
Number of subjects: 1005
Study 16227760 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ 300/25 mg for 8 weeks
Number of subjects: 1005
Study 16227760 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/HCTZ treatment regimen
Number of subjects: 1005
Study 11863257 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat (target dose 40 mg once daily)
Number of subjects: 12600
Study 11863257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12600
Study 11863257 — intervention group
Group type: EXPERIMENTAL
Intervention: Omapatrilat
Number of subjects: 12600
Study 10030553 — intervention group
Group type: EXPERIMENTAL
Intervention: Photocoagulation
Number of subjects: 3711
Study 10030553 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 3711
Study 10030553 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 3711
Study 7747690 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose levosimendan (25 micrograms/kg)
Number of subjects: 14
Study 7747690 — intervention group
Group type: COMPARATOR
Intervention: High dose levosimendan (25 micrograms/kg) during exercise at lower workload
Number of subjects: 14
Study 7747690 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose levosimendan (6.5 micrograms/kg)
Number of subjects: 14
Study 7747690 — intervention group
Group type: COMPARATOR
Intervention: High dose levosimendan (25 micrograms/kg) at higher workload
Number of subjects: 14
Study 1294521 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g)
Number of subjects: 349
Study 1294521 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (1.92 g)
Number of subjects: 349
Study 1294521 — intervention group
Group type: COMPARATOR
Intervention: Ofloxacin (200 mg)
Number of subjects: 349
Study 6733833 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mile continuous running at 75% of maximal heart rate (approximately 500 Cal/session)
Number of subjects: 59
Study 6733833 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mile continuous running at 75% of maximal heart rate (approximately 250 Cal/session)
Number of subjects: 59
Study 6733833 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval running (1 min at 90% maximal heart rate followed by 3 min walking for eight sets, approximately 500 Cal/session)
Number of subjects: 59
Study 6733833 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise program)
Number of subjects: 59
Study 30761717 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (CTZ) 200 mg/d
Number of subjects: 100
Study 30761717 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (ASA) 100 mg/d
Number of subjects: 100
Study 29412363 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (400 mg) administered 1 hour prior to bleaching
Number of subjects: 50
Study 29412363 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour prior to bleaching
Number of subjects: 50
Study 25091062 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial susceptibility-guided therapy
Number of subjects: 114
Study 25091062 — intervention group
Group type: COMPARATOR
Intervention: Clarithromycin-based triple therapy
Number of subjects: 114
Study 22595172 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care 30 minutes (KC30)
Number of subjects: 26
Study 22595172 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Care 15 minutes (KC15)
Number of subjects: 26
Study 22595172 — intervention group
Group type: COMPARATOR
Intervention: Incubator Care (IC)
Number of subjects: 26
Study 22595172 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (KC30, KC15, IC)
Number of subjects: 26
Study 19246508 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, bismuth subcitrate, tetracycline and metronidazole (EBTM)
Number of subjects: 166
Study 19246508 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole, amoxicillin and levofloxacin (EAL)
Number of subjects: 166
Study 19246508 — intervention group
Group type: COMPARATOR
Intervention: EBTM
Number of subjects: 166
Study 19246508 — intervention group
Group type: COMPARATOR
Intervention: EAL
Number of subjects: 166
Study 17478453 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (group US, n = 30)
Number of subjects: 60
Study 17478453 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulation guidance (group NS, n = 30)
Number of subjects: 60
Study 15067189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance method for predicting total body water (TBW)
Number of subjects: 70
Study 12565715 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin (2 mg per day)
Number of subjects: 103
Study 12565715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 12565715 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 103
Study 9514421 — intervention group
Group type: EXPERIMENTAL
Intervention: Oophorectomy
Number of subjects: 155
Study 9514421 — intervention group
Group type: COMPARATOR
Intervention: Nonoophorectomy
Number of subjects: 155
Study 7822572 — intervention group
Group type: EXPERIMENTAL
Intervention: Postconditioning rehearsal of the unconditioned stimulus (UCS) in subjects with high levels of trait anxiety
Number of subjects: 0
Study 7822572 — intervention group
Group type: EXPERIMENTAL
Intervention: Postrehearsal in subjects with induced somatic anxiety
Number of subjects: 0
Study 7822572 — intervention group
Group type: COMPARATOR
Intervention: Induced worrying or neutral induction procedure
Number of subjects: 0
Study 3046414 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 mg/kg)
Number of subjects: 20
Study 3046414 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 20
Study 31353988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational-emotive behaviour therapy
Number of subjects: 23
Study 31353988 — intervention group
Group type: COMPARATOR
Intervention: Counselling (Control)
Number of subjects: 23
Study 29380761 — intervention group
Group type: EXPERIMENTAL
Intervention: Optisol-GS preservative medium (Group A)
Number of subjects: 20
Study 29380761 — intervention group
Group type: COMPARATOR
Intervention: Transfer from MK medium to Optisol-GS (Group B)
Number of subjects: 20
Study 28329434 — intervention group
Group type: EXPERIMENTAL
Intervention: COPE treatment (Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure)
Number of subjects: 31
Study 25691362 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback overstating true rotation
Number of subjects: 24
Study 25691362 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback understating true rotation
Number of subjects: 24
Study 25691362 — intervention group
Group type: COMPARATOR
Intervention: Accurate visual feedback
Number of subjects: 24
Study 23078045 — intervention group
Group type: EXPERIMENTAL
Intervention: Achieve catheter (AC)
Number of subjects: 32
Study 23078045 — intervention group
Group type: COMPARATOR
Intervention: Control group (single transseptal approach)
Number of subjects: 32
Study 20601736 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF; 3.7 mg/kg BM)
Number of subjects: 15
Study 20601736 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate (CON; 1.8 g/kg BM)
Number of subjects: 15
Study 18410762 — intervention group
Group type: EXPERIMENTAL
Intervention: OGTT (Oral Glucose Tolerance Test)
Number of subjects: 26
Study 18410762 — intervention group
Group type: EXPERIMENTAL
Intervention: Boost test (liquid mixed-meal test)
Number of subjects: 26
Study 18410762 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycemic clamp test (Hyper-C)
Number of subjects: 26
Study 16637728 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Prompt L‐pop
Number of subjects: 40
Study 16637728 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid + Transbond XT primer
Number of subjects: 40
Study 14509861 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐behavioural stress management/expressive supportive therapy (CBSM+) intervention
Number of subjects: 174
Study 14509861 — intervention group
Group type: COMPARATOR
Intervention: Individual control condition
Number of subjects: 174
Study 11002624 — intervention group
Group type: EXPERIMENTAL
Intervention: subsyde-CR (diclofenac in controlled release formulation using DRCM technology)
Number of subjects: 0
Study 11002624 — intervention group
Group type: COMPARATOR
Intervention: meloxicam (standard formulation)
Number of subjects: 0
Study 8946307 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography screening
Number of subjects: 156911
Study 8946307 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 156911
Study 1430680 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter monitoring with ST segment depression
Number of subjects: 109
Study 1430680 — intervention group
Group type: COMPARATOR
Intervention: Holter monitoring without ST segment depression
Number of subjects: 109
Study 1430680 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) treatment
Number of subjects: 109
Study 3907334 — intervention group
Group type: EXPERIMENTAL
Intervention: High-nitrogen, low-carbohydrate diet (experimental diet)
Number of subjects: 12
Study 3907334 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control diet (control group)
Number of subjects: 12
Study 30693366 — intervention group
Group type: EXPERIMENTAL
Intervention: Collegial discussions on patient cases (two 3-hour seminars)
Number of subjects: 69
Study 30672177 — intervention group
Group type: EXPERIMENTAL
Intervention: Grain-moxibustion combined with acupuncture
Number of subjects: 88
Study 30672177 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 88
Study 26633836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg bid for seven days
Number of subjects: 30
Study 26633836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 23975053 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxin A (Vistabel®)
Number of subjects: 16
Study 23975053 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 22341062 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Universal System
Number of subjects: 40
Study 22341062 — intervention group
Group type: EXPERIMENTAL
Intervention: SybronEndo K3 System
Number of subjects: 40
Study 22341062 — intervention group
Group type: COMPARATOR
Intervention: H-files
Number of subjects: 40
Study 22341062 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 19789433 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive directed breathing retraining
Number of subjects: 24
Study 19789433 — intervention group
Group type: COMPARATOR
Intervention: Traditional diaphragmatic breathing
Number of subjects: 24
Study 18034990 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol for sedation
Number of subjects: 250
Study 18034990 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate sedation (OAA/S score of 3)
Number of subjects: 250
Study 18034990 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-controlled infusion of propofol
Number of subjects: 250
Study 18034990 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sedation levels
Number of subjects: 250
Study 16130506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral disodium pamidronate combined with calcium salts and vitamin D3 supplements
Number of subjects: 0
Study 16130506 — intervention group
Group type: COMPARATOR
Intervention: Calcium salts and vitamin D3 supplements alone
Number of subjects: 0
Study 12193919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal misoprostol (800 microg)
Number of subjects: 50
Study 12193919 — intervention group
Group type: COMPARATOR
Intervention: Surgical therapy (dilatation and curettage)
Number of subjects: 50
Study 10206802 — intervention group
Group type: EXPERIMENTAL
Intervention: Dodecafluoropentane
Number of subjects: 16
Study 7771602 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG powder sprinkled on flavored gelatin
Number of subjects: 0
Study 7771602 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2126114 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 or more days of metronidazole and cefazolin prophylaxis
Number of subjects: 50
Study 2126114 — intervention group
Group type: COMPARATOR
Intervention: 2 days of metronidazole and cefazolin prophylaxis
Number of subjects: 50
Study 368533 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone sodium
Number of subjects: 40
Study 368533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31529047 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D with previous preeclampsia (T1D+/PE+; n = 28)
Number of subjects: 112
Study 31529047 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D without preeclampsia (T1D+/PE-; n = 28)
Number of subjects: 112
Study 31529047 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous preeclampsia without T1D (T1D-/PE+; n = 28)
Number of subjects: 112
Study 31529047 — intervention group
Group type: COMPARATOR
Intervention: Controls without T1D or PE (T1D-/PE-; n = 28)
Number of subjects: 112
Study 31529047 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D+/PE- or T1D-/PE+
Number of subjects: 112
Study 31529047 — intervention group
Group type: EXPERIMENTAL
Intervention: T1D+/PE+
Number of subjects: 112
Study 30028021 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fluoride dentifrice (5,000 ppm fluoride)
Number of subjects: 0
Study 30028021 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentifrice (1,450 ppm fluoride)
Number of subjects: 0
Study 30028021 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher income and more years of formal education
Number of subjects: 0
Study 27891702 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer-PEPSONE programme (CPP)
Number of subjects: 35
Study 27891702 — intervention group
Group type: COMPARATOR
Intervention: Support as usual (control)
Number of subjects: 35
Study 26049727 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 206
Study 26049727 — intervention group
Group type: COMPARATOR
Intervention: Conventional diuretics
Number of subjects: 206
Study 24268031 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Burch colposuspension (LBC)
Number of subjects: 96
Study 20814410 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Number of subjects: 0
Study 20814410 — intervention group
Group type: COMPARATOR
Intervention: TAG oil (15% of total caloric intake, mean intake 33.0 ± 3.1 g/day)
Number of subjects: 0
Study 19486955 — intervention group
Group type: EXPERIMENTAL
Intervention: IC51 (Japanese Encephalitis vaccine)
Number of subjects: 0
Study 19486955 — intervention group
Group type: EXPERIMENTAL
Intervention: HAVRIX1440 (hepatitis A vaccine)
Number of subjects: 0
Study 19486955 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant vaccination (IC51 and HAVRIX1440)
Number of subjects: 0
Study 19486955 — intervention group
Group type: COMPARATOR
Intervention: Single vaccination (IC51 or HAVRIX1440)
Number of subjects: 0
Study 17113441 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral sagittal split osteotomy (BSSO) only, with or without genioplasty; BSSO + Le Fort I, with or without genioplasty
Number of subjects: 146
Study 17113441 — intervention group
Group type: EXPERIMENTAL
Intervention: BSSO + Le Fort I
Number of subjects: 146
Study 17113441 — intervention group
Group type: EXPERIMENTAL
Intervention: Genioplasty
Number of subjects: 146
Study 15522050 — intervention group
Group type: EXPERIMENTAL
Intervention: (99m)Tc-sestamibi during exercise
Number of subjects: 31
Study 15522050 — intervention group
Group type: COMPARATOR
Intervention: (99m)Tc-sestamibi during dipyridamole stress testing
Number of subjects: 31
Study 11748390 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg spinal ropivacaine
Number of subjects: 72
Study 11748390 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg spinal ropivacaine
Number of subjects: 72
Study 11748390 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg spinal ropivacaine
Number of subjects: 72
Study 11748390 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg spinal ropivacaine
Number of subjects: 72
Study 9284668 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (withdrawal group, n = 102)
Number of subjects: 202